CordenPharma is honored to announce the receipt of a Supplier Recognition Award from Esperion Therapeutics that was presented by Esperion’s Sr. Vice President of Manufacturing Planning & Operations Nilay Vashi to CordenPharma CEO Dr. Michael Quirmbach during DCAT Week 2022 in New York City.

The award marks CordenPharma’s manufacturing excellence in supporting the commercial launch of Esperion’s Nexletol^® and Nexlizet^® with the the scale-up, validation and commercial production of its Active Pharmaceutical Ingredient (API) Bempedoic Acid in CordenPharma Colorado. Since 2016, CordenPharma has been working with Esperion as a CDMO supplier for the API to treat hypercholesterolemia.

CordenPharma CEO & President Dr. Michael Quirmbach comments, “We very much appreciate this recognition by Esperion as a trusted CDMO partner, which underlines the CordenPharma commitment to support innovative Biotech and Pharma companies to bring new medicines to patients. As a team, we are proud to have contributed to the launch of this innovative and first-class medication for the treatment of hypercholesterolemia.”

Find out more in the press release.